BioXcel Therapeutics, Inc. Provides Corporate and Financing Updates

Strategic Insights -

BioXcel Therapeutics, Inc. recently filed a FORM 8-K with the U.S. Securities and Exchange Commission, outlining key corporate and financing updates. The Company completed enrollment in its open-label clinical study, examining the correlation between patient-reported CGI-S measurement and the PEC scale, conducted by trained raters. The study is expected to release results in the fourth quarter of 2025, with results including the SERENITY At-Home Pivotal Phase 3 Safety Trial contributing to the clinical package for the sNDA submission. The Company also provided updates on its financing and liquidity, reporting an aggregate of $37.3 million raised through the sale of shares under its ATM Program and the exercise of outstanding warrants between July 1, 2025, and September 15, 2025.

Key Takeaways:

  • BioXcel Therapeutics, Inc. completed enrollment in its open-label clinical study on September 13, 2025, aimed at evaluating the correlation between patient-reported CGI-S measurement and the PEC scale.
  • The Company expects to release the results of the study in the fourth quarter of 2025, with the results, along with the SERENITY At-Home Pivotal Phase 3 Safety Trial, contributing to the clinical package for the sNDA submission.
  • BioXcel Therapeutics, Inc. raised an aggregate of $37.3 million through the sale of shares under its ATM Program and the exercise of outstanding warrants between July 1, 2025, and September 15, 2025.
  • The Company's existing cash and cash equivalents, totaling approximately $27.6 million, are expected to be sufficient to fund operating expenses and capital expenditure requirements into the first quarter of 2026.
  • BioXcel Therapeutics, Inc. anticipates completing its sNDA submission before the end of the year, and the Company looks forward to submitting substantial evidence to support the approval of its product candidate.
  • The Company also reiterated its commitment to ensuring its liquidity and capital resources are sufficient to maintain operations and achieve its business objectives.
  • As of August 18, 2025, the Company filed a further prospectus supplement with the Securities and Exchange Commission in connection with the offer and sale of an additional $80.0 million shares pursuant to the ATM Program.
  • On August 6, 2025, the Company filed a prospectus supplement with the Securities and Exchange Commission in connection with the offer and sale of an additional $3.5 million shares pursuant to the ATM Program.
  • The Company entered into an Equity Distribution Agreement with Canaccord Genuity LLC to sell shares of Common Stock through any method permitted that is deemed an "at the market offering" as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended.

Statistics:

  • $37.3 million: Aggregate amount raised through the sale of shares under the ATM Program and the exercise of outstanding warrants between July 1, 2025, and September 15, 2025.
  • $27.6 million: Aggregate gross proceeds from the sale of 9,312,892 shares under the ATM Program.
  • $9.7 million: Aggregate gross proceeds from the exercise of outstanding warrants to purchase a total of 2,300,000 shares.
  • $80.0 million: Additional amount raised through the sale of shares pursuant to the ATM Program on August 18, 2025.
  • 19,646,801: Total shares of outstanding stock as of September 12, 2025.

Sources:

  • BioXcel Therapeutics, Inc. (Exact name of registrant as specified in its charter)
  • UNITED STATES SECURITIES AND EXCHANGE COMMISSION
  • Securities and Exchange Act of 1934
  • RULE 415(a)(4) under the Securities Act of 1933, as amended.